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Long-term treatment with senolytic drugs
Dasatinib and Quercetin ameliorates agedependent intervertebral disc degeneration in mice
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Emanuel J. Novais1,2,3,4, Victoria A. Tran1, Shira N. Johnston 1,2, Kayla R. Darris5,6, Alex J. Roupas5,6,
Garrett A. Sessions5,6, Irving M. Shapiro1,2, Brian O. Diekman5,6 & Makarand V. Risbud 1,2 ✉

Intervertebral disc degeneration is highly prevalent within the elderly population and is a
leading cause of chronic back pain and disability. Due to the link between disc degeneration
and senescence, we explored the ability of the Dasatinib and Quercetin drug combination
(D + Q) to prevent an age-dependent progression of disc degeneration in mice. We treated
C57BL/6 mice beginning at 6, 14, and 18 months of age, and analyzed them at 23 months of
age. Interestingly, 6- and 14-month D + Q cohorts show lower incidences of degeneration,
and the treatment results in a signiﬁcant decrease in senescence markers p16INK4a, p19ARF,
and SASP molecules IL-6 and MMP13. Treatment also preserves cell viability, phenotype, and
matrix content. Although transcriptomic analysis shows disc compartment-speciﬁc effects of
the treatment, cell death and cytokine response pathways are commonly modulated across
tissue types. Results suggest that senolytics may provide an attractive strategy to mitigating
age-dependent disc degeneration.
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he prevalence and impact of age-dependent diseases is
increasing with increased human lifespan. In a recent
global survey of 50 chronic pathological conditions, low
back pain (LBP) and neck pain ranked the 1st and 4th top causes
of years lived with disability1. Although the etiology of LBP is
multifactorial, intervertebral disc degeneration is regarded as a
major contributor to this pathology2. Importantly, aging exacerbates disc degeneration and disease progression, giving rise to an
urgent need to understand the underlying mechanisms of disc
aging and develop solutions to delay or ameliorate the progression of age-dependent degeneration2,3.
The intervertebral disc confers ﬂexibility and plays a key role in
accommodating the mechanical loads applied to the spinal column. These functional properties are enabled by the interaction
of three unique disc compartments: the central nucleus pulposus
(NP)—an avascular tissue, rich in aggrecan; the circumferential,
ligamentous annulus ﬁbrous (AF)—primarily composed of collagen ﬁbers; and the cartilaginous endplates (CEP) bordering the
NP and AF on cranial and caudal surfaces. It is now recognized
that abnormal function of any of these compartments can
inﬂuence degeneration of the others3,4. Deﬁning features of disc
degeneration include decreased abundance and quality of extracellular matrix (ECM), loss of biomechanical properties, an
increase in inﬂammatory mediators and catabolic processes, and
changes in cell phenotype and death5–7. Despite widespread
prevalence and disease burden, no disease-modifying treatments
are currently available for disc degeneration and associated
pathologies.
Studies of human tissues and mouse models have shown an
increased incidence of senescent cells during intervertebral disc
aging and degeneration8–11. Senescent cells are broadly characterized by cell cycle arrest, apoptotic-resistance, and the production of catabolic factors known as the senescence-associated
secretory phenotype (SASP)12,13. Senescence can be induced in
response to a variety of stimuli, including telomere attrition,
oncogenes, and cell stress (e.g., oxidative, genotoxic, cytokines),
which can contribute to SASP activation and senescence
transformation12,13. Increased expression of cell cycle inhibitors
p21, p53, and p16INK4a are responsible for maintaining the stable
arrest of senescence. Alterations to cell division are accompanied
by an increase in cytokines, chemokines, and other SASP proteins. These phenotypic changes culminate in inﬂammation,
ﬁbrosis, loss of regenerative capacity, and ultimately tissue
degeneration13. Recently, we analyzed AcanCreERT2;p16Ink4a
conditional knockout mice and found decreased levels of cell
death, SASP, and aberrant matrix changes in the discs of aged
mice11. This ﬁnding is supported by reduced oxidative stress and
disc degeneration in Cdkn2a germline knockout mice in response
to a tail suspension injury model14. Additionally, Patil et al.10
used genetically engineered p16-3MR transgenic mice to
demonstrate that systemic clearance of p16INK4a-positive cells
mitigated age-related disc degeneration by reducing matrix catabolism and senescent cells in the disc compartment. Similarly,
Cherif et al.15,16 showed effective clearing of senescent disc cells
and reduction in inﬂammatory signaling using senolytics RG7112 and o-Vanillin in ex vivo and in vitro assay systems. While
these studies implicate senescent cells in driving disc pathology, it
remains to be established if senolytic drugs can slow, cure, or even
prevent disc degeneration during physiological aging in vivo.
The concept of senolytic therapy is that apoptosis can be
selectively initiated in senescent cells by inhibiting the prosurvival mechanisms upregulated during senescence. Zhu et al.17
ﬁrst demonstrated this concept by suppressing the pro-survival
BCL-XL and EFNB1 pathways that are highly activated by
senescent cells, and other senolytic targets have emerged18–20. Of
note, the combination of Dasatinib (D)—a Src/tyrosine kinase
2

inhibitor—and Quercetin (Q)—a natural ﬂavonoid that binds to
BCL-2 and modulates transcription factors, cell cycle proteins,
pro- and anti-apoptotic proteins, growth factors and protein
kinases21,22—has been used extensively as a senolytic. The D + Q
combination has shown beneﬁcial effects in idiopathic pulmonary
ﬁbrosis23, bone loss24, and improved physical condition and
lifespan25. In recent human clinical trials, D + Q reduced the
number of senescent cells and improved physical
performance26,27. Cognizant of these results, we investigated the
therapeutic potential of D + Q in the context of disc degeneration. Accordingly, we treated wild-type C57BL/6 (BL6) mice
beginning at: 6 months—to prevent disc degeneration onset
(skeletally mature mice with healthy discs); 14 months—to bar
progression of disc degeneration (middle-aged mice with early
signs of degeneration); and 18 months—to rescue established disc
degeneration (elderly mice with visible degeneration) up to
23 months of age. Our results show that there is a time-dependent
effect of the D + Q senolytic cocktail on restoring disc health.
This work provides important in vivo evidence that D + Q can, in
a non-invasive manner, target senescent cells and mitigate the
effects of age-dependent disc degeneration.
Results
Dasatinib and Quercetin treatment alleviates age-dependent
intervertebral disc degeneration and decreases senescence
burden. Senescence plays an essential role in intervertebral disc
aging pathology and disease progression10,11,14. To date, no pharmacological approaches to prevent age-related disc degeneration
exist. We treated 6-, 14-, and 18-month-old wild-type C57BL/6
(BL6) mice up to 23 months (6–23 M, 14–23 M, 18–23 M), with a
weekly injection of a Dasatinib (D) and Quercetin (Q) combination
to target senescent cells and prevent and/or treat age-related disc
degeneration (Fig. 1a). Histological analysis of lumbar discs from
6–23 M and 14–23 M D + Q cohorts showed better preservation of
tissue and cell morphology, with maintenance of NP/AF compartment demarcation and the NP cell band and a lower number of AF
clefts relative to Vehicle-treated control animals (Veh) (Fig. 1b and
Supplementary Fig. 1a). By contrast, mice in 18–23 M cohort did not
show any signiﬁcant improvements in disc morphology relative to
the Veh group (Supplementary Fig. 1b). Histological grades of
degeneration for lumbar levels were recorded using a modiﬁed
Thompson grading system28,29. Grade distributions as well as
combined average grades showed lower scores of degeneration in the
NP and AF compartments of 6–23 M and 14–23 M D + Q cohorts
in comparison to respective Veh groups (Fig. 1c, d). Level-by-level
analysis of NP degeneration scores showed signiﬁcantly lower grades
in L4-5 and L5-6 in 6–23 M and 14–23 M D + Q mice, respectively,
trending toward lower grades at other levels (Fig. 1e and Supplementary Fig. 1c). Similarly, level-by-level analysis of AF degeneration
grades showed a signiﬁcant decrease in scores at L3-4 and L5-6 in
the 14–23 M cohort, and grades trended downward in the 6–23 M
cohort (Fig. 1e and Supplementary Fig. 1d). Supporting histological
observations, the 18–23 M D + Q group presented grade distributions, as well as similar pooled and level-by-level average grades
comparable to the Veh group (Supplementary Fig. 1c, d). Together,
these results provide strong evidence that D + Q treatment mitigates
age-related disc degeneration, a key intervention window exists, and
the disease status at the start of the treatment is crucial for therapeutic success.
To evaluate the potential of D + Q in decreasing senescence
burden in the disc, we evaluated the abundance of key senescence
markers. The 14–23 M cohort was selected for this and
subsequent analyses, since these mice showed the most
pronounced response to treatment in their disc morphology.
Additionally, 14-month-old C57BL/6 mice exhibit early
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morphological changes associated with age-related disc
degeneration6 and better represent the middle-aged human
patient population (ages 40–50 years) with increased LBP
prevalence seeking clinical treatments30. Interestingly, both
p16INK4a and p19ARF, well known markers of senescence
in vivo, showed decreased abundance in D + Q-treated discs

(Fig. 1f–g’, i)12,13,31–33. Similarly, levels of p21, a potent cell cycle
inhibitor and key downstream mediator of senescence, was also
decreased in the D + Q group (Fig. 1h–i)34. Moreover, while
there were no changes in levels of cell cycle inhibitor RB, levels of
pRB were lower in D + Q-treated disc (Supplementary Fig. 2a–d).
The decrease in senescence burden by D + Q in disc was not
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Fig. 1 Senolytic drugs Dasatinib and Quercetin alleviate age-dependent intervertebral disc degeneration and decrease abundance of senescence
markers. a Schematic showing study design: peritoneal injections were administered once every week to mice starting at 6 (6 M), 14 (14 M), or 18 (18 M)
months of age and ending at 23 (23 M) months of age. Vehicle (1:1 PBS/DMSO), D + Q (5 mg/kg Dasatinib plus 50 mg/kg Quercetin). b Histology of the
14–23 M cohort showed preservation of tissue architecture and cell morphology in the NP, AF, and CEP of D + Q-treated mice. 5X and 20X images of
14–23 M show NP, AF, and CEP compartment morphologies. c, d Modiﬁed Thompson Grading averages and grade distributions showed lower average
scores of degeneration in mice that were treated from 6 M and 14 M. Mice in 18–23 M D + Q cohort showed comparable scores the Veh group. e Level-bylevel analysis of L3-6 in the lumbar spine evidenced decreases in degeneration grades in the NP compartment at L5-6 and in the AF compartment at L3-4
and L5-6. f–j Staining and abundance of key markers of senescence p16INK4a, p19ARF and p21, and cell cycle: Ki67 in disc compartments. Two-tailed t-test
or Mann–Whitney test were used as appropriate for comparing differences between Veh and D + Q groups. 6–23 M Veh (n = 13), D + Q (n = 15); 14–23 M
Veh (n = 8), D + Q (n = 7); 18–23 M Veh (n = 11), D + Q (n = 9). Data are represented as mean ± SEM. Scale bar b (disc) = 200 µm; Scale bar b (NP, AF,
and CEP) = 50 µm; Scale bar f–f’, g–g’, i–i’, and j–j’ = 200 µm. NP: nucleus pulposus; AF: annulus ﬁbrosus; EP: endplate; GP: growth plate, VB: vertebral
bone. Source data are provided as a Source Data ﬁle.

accompanied by cell proliferation as seen by comparable and low
levels of Ki67 staining (Fig. 1j–j’). Of note, the 18–23 M D + Q
group, which did not present any alleviation in disc degeneration,
showed similar abundance of senescence markers p16INK4a,
p19ARF, and RB compared to Veh treatment (Supplementary Fig.
2e–g”). Altogether, these results suggest that long-term treatment
of D + Q successfully targets and reduces the number of
senescent cells in the intervertebral disc.
D + Q treatment mitigated age-dependent progression of
SASP and preserved NP cell phenotype and viability. SASP is
known to promote tissue inﬂammation, catabolism, and ﬁbrosis,
which contribute to the progression of degenerative pathologies13.
To study the age-dependent progression of SASP markers in the
disc and whether they are responsive to D + Q, we evaluated the
abundance of IL-1β, IL-6, and MMP13 (Fig. 2a–c”’), wellestablished SASP markers in different tissues, including the
intervertebral disc10,11,18,35. In addition to the Veh and D + Q
groups (14–23 M cohort), we analyzed 1-year-old BL6 (1 y Ctr)
mice as a reference for the healthy adult state and to understand
the effect of aging on measured parameters. Quantitative
immunohistochemical analyses showed reductions in IL-6 and
MMP13 in both D + Q and 1 y Ctr relative to the Veh group
(Fig. 2b, c”’). In contrast, higher levels of IL-1β were seen in
D + Q and 1 y Ctr groups (Fig. 2a–a”’). To investigate the effects
of D + Q on NP cell phenotype and disc cell viability, CA3 and
GLUT1 abundance were assessed36, and TUNEL staining was
performed. While NP cells from D + Q-treated and 1 y Ctr mice
robustly expressed CA3 and GLUT1, the Veh group showed
decreased abundance of these markers (Fig. 2d, e”’). Moreover,
discs of D + Q-treated mice showed higher cellularity and lower
percentages of TUNEL-positive cells (Fig. 2f–f”’). Interestingly,
discs from 1 y Ctr mice had comparable cell counts and percentages of TUNEL-positive cells with the D + Q cohort
(Fig. 2f–f”’), suggesting a cytoprotective effect of the treatment on
cells. Together, these results suggest that D + Q treatment
decreases SASP and preserves NP cell phenotype and viability
during aging.
D + Q treatment preserved healthy ECM and limited Aggrecan
degradation during aging. Integrity of the ECM is vital to proper
disc function. Importantly, aging promotes ECM catabolism,
leading to decreased levels of proteoglycans and collagens37 and
compromised tissue function38. COL1, COL2, and COMP
abundances were lower in discs from the Veh group (14–23 M
cohort) compared to the 1 y Ctr (Fig. 3a–c”’). Interestingly, while
COL2 levels did not change in D + Q group, COL1 and COMP
levels were higher compared to the Veh group (Fig. 3a–c”’).
Moreover, COLX, a collagen type highly expressed during disc
degeneration7, was present at lower levels in both 1 y Ctr and
4

D + Q groups compared to the Veh group (Fig. 3d–d”’). Chondroitin sulfate is a functional constituent of aggrecan, a proteoglycan responsible for water binding and viscoelastic
properties of the disc39. Despite comparable abundance of CS
between 1 y Ctr and Veh groups, D + Q-treated mice showed
higher abundance of CS compared to the Veh group (Fig. 3e–e”’).
Additionally, abundance of ARGxx, a degradation product generated following aggrecan cleavage, was signiﬁcantly lower in
discs of D + Q-treated mice compared to the Veh-treated group
(Fig. 3f’–f”’). However, there were no signiﬁcant differences in
overall abundance of ARGxx levels between the discs of 1 y Ctr
and Veh animals, suggesting that aggrecan turnover likely begins
earlier than thought (Fig. 3f–f’). These results suggest that D + Q
treatment helps mitigate the loss of disc ECM with aging.
D + Q treatment reduces nucleus pulposus ﬁbrosis during
aging. Fibrosis is one of the main degenerative disc phenotypes
promoted by aging28. Collagen content, as measured by imaging
FTIR spectroscopy, showed lower levels in the NP compartment of
D + Q-treated mice when compared to Veh-treated animals
(Fig. 4a, b). Similarly, Picrosirius Red staining with polarized
microscopy showed that only 12% of D + Q discs possessed distinct
collagen ﬁbers within the NP compartment. The vehicle group
had collagen ﬁbers in 50% of discs, whereas there were no quantiﬁable collagen ﬁbers in the NP from 1-year controls (Fig. 4c, d).
Assessment of collagen ﬁber thickness in the AF compartment
showed that D + Q group presented the lowest percentage of thick
ﬁbers (red) and an overall increase in thin ﬁbers (green) as compared to Veh and 1-year Ctr mice (Fig. 4d, e). We also assessed the
collagen quality and integrity by treating disc sections with ﬂuorescently labeled collagen hybridizing peptide (CHP), which selectively binds to denatured collagen40. There were no differences in
CHP binding among the groups (Fig. 4f).
D + Q treatment resulted in distinct transcriptomic modulation in AF and NP compartments. Microarray analysis was
performed on AF and NP tissues from discs of 14–23 M Veh- and
D + Q-treated mice. Baseline differences between AF and NP
compartments were ﬁrst assessed by analyzing the differentially
expressed genes (DEGs) between AF-Veh and NP-Veh with a
cutoff of p < 0.05 (Fig. 5a–c and Supplementary Fig. 3). The
transcriptomic proﬁles of each tissue clustered distinctly, as
demonstrated by principal component analysis (Fig. 5a), and a
similar number of the 10,283 total DEGs were upregulated in
each tissue (Supplementary Fig. 3a). Expectedly, NP tissue
showed higher levels of Krt19, Slc2a1, and Car3, well-established
markers of the NP compartment; the AF presented higher levels
of Col1a2, Comp, and Ibsp, known hallmarks of the AF compartment (Fig. 5b)41,42. Importantly, each tissue presented with
unique regulation of genes related to the ECM, focal adhesions,
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Fig. 2 D + Q treatment prevents age-dependent SASP progression and promotes NP cell phenotype maintenance and disc cell viability. a–c”’
Immunohistological staining and staining area quantiﬁcations of SASP markers IL-1, IL-6, and MMP13 in the disc compartments of 1-year-old healthy Ctr
(1 y Ctr), 14–23 M Veh-, and 14–23 M D + Q-treated mice. d–e”’ Quantitative immunostaining of NP cell phenotypic markers CA3 and GLUT1. f–f”’ Cell
death assessment in the disc compartments by TUNEL staining. Two-tailed ANOVA or Kruskal–Wallis tests were used as appropriate; n = 6 mice/group,
2–3 levels per mouse. Data are represented as mean ± SEM. Scale bar = 200 µm. Source data are provided as a Source Data ﬁle.

and phenotype regulation in 23-month-old mice (Supplementary
Fig. 3b, c). Additionally, related to regulation of the cell cycle,
higher levels of Cdkn2d, Ccnd2, Pcna, and E2f2 were seen in the
AF, while the NP compartment showed elevated levels of Cdkn1c,
Cdkn1b, Cdkn2b, Ccnd1, and Atm (Fig. 5c). This data suggests
that AF and NP compartments present distinct transcriptomic
proﬁles at 23-months, with divergent regulation of critical biological pathways, including the cell cycle.
To explore the biological pathways targeted by D + Q
treatment in each disc compartment, AF D + Q and Veh groups

were compared, identifying 1,646 DEGs. Of these, 65% were
upregulated, and 35% were downregulated in the D + Q group;
p < 0.05 (Fig. 5d and Supplementary Fig. 4a, b). To understand
the biological impact of these DEGs, gene enrichment analysis of
these up- and downregulated DEGs groups was performed using
the Overrepresentation Test in PANTHER43. The DEGs
upregulated in the AF of D + Q-treated mice showed enrichment
of G protein-coupled receptor (GPCR) signaling, response to
stress, mitotic cell cycle, cellular response to DNA damage
stimulus, cell adhesion, and DNA repair pathways (Fig. 5e). We
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found several AF DEGs associated with negative regulation of cell
death: Hhip, C7, Pcp4, Cntfr, Il2, Serpinb13, Card13, and Il7;
mitotic cell cycle: Slxl1, Morc2b, Stard9, Piwil2, Rab11, ﬁp3,
Trim36, Irf6, Myog, and Tppp; and DNA repair and response to
stress: Cd36, Mid1, Morc2b, Vsig4, Ccr7, Spo11, Gpx2, Serpinb3a,
Ccl1, Mink1, Il2, Il21, and Cxcl5 (Supplementary Fig. 4c). On the
other hand, downregulated AF DEGs were enriched for ribosome
biogenesis, mitochondria organization, cellular respiration,
response to cytokines, ATP metabolic process, regulation of cell
death, as well as GPCR signaling (Fig. 5f). Noteworthy DEGs
were identiﬁed in relation to cellular respiration: Atp5d, Atp5f1,

Atp5o, Atp5g1, Ndufs8, Nduf7, Ndufc2, Ndufb5, Ndufb8, Sdhd,
Dld, Cox6a1, and Sdhaf2; ribosome biogenesis: Upt3, Rpl38,
Rps16, Ddx52, Rps15, Rps17, Rps21, Rps5, Rpl38, Rpl6, Mrpl20,
and Fastkd2; and response to cytokines: Myc, Socs3, Nﬁl3, Junb,
Mcl1, Irf1, Klf6, Hsp90aa1, Vamp8, Icam1, Cebpb, Tnfrsf1a, Igbp1,
Il6ra, Hspa5, Mapk3, Cd14, and Irak2 (Supplementary Fig. 4d).
Analysis of DEGs comparing NP D + Q and Veh groups
identiﬁed 964 DEGs, of which 54% were upregulated, and 46%
downregulated, p < 0.05 (Fig. 5g and Supplementary Fig. 4e, f).
Importantly, DEGs downregulated in the D + Q group showed
enrichment in the regulation of DNA-templated transcription in
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response to stress, skeletal muscle cell differentiation, regulation
of cell death, protein kinase activity, apoptotic process, transcription by RNA polymerase II, and regulation of phosphorylation
pathways (Fig. 5h). Noteworthy DEGs were identiﬁed in relation
to skeletal muscle cell differentiation: Atf3, Nr4a1, Btg2, Maff,
Egr1, Sap30, Scx, and Asb2; transcription by RNA polymerase II:
Fosb, Fos, Junb, Jun, Nﬁl3, Egr2, Atf4, and Jund; regulation of
protein kinase activity: Errﬁ1, Gadd45g, Dusp6, Egr1, Cyr61,
8

Dusp1, Dusp8, Taf7, Hspb1, Efna1, Cdkn2d, Sesn2, Pdgfc,
Mapk3k2, and Gadd45b; and regulation of cell death: Pim1,
Cyr61, Klf4, Serpine1, Id3, Mcl1, Rhob, Pim3, Efna1, Axl, Myc,
Itga5, Eif2b5, Cdh1, Aven, and Bdnf (Supplementary Fig. 4g).
Interestingly, DEGs upregulated in the D + Q-treated NP showed
enrichment for zinc ﬁnger transcription factor, defense/immunity
protein, and immunoglobin related molecular classes (Supplementary Fig. 4h, i). Some of these genes include Ersr1, Ppox,
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Fig. 5 D + Q treatment promoted transcriptomic modulation of cell death, response to cytokines, regulation of RNA polymerase II, and the ERK1/
ERK2 cascade in AF and NP compartments. a Transcriptomic proﬁles of AF (n = 5) and NP (n = 5) tissues from 14–23 M Veh mice clustered distinctly
with principal component analysis. b Volcano Plot, showing up- and downregulated DEGs from the 23 M AF vs. NP comparison used for GO Process
enrichment analysis, p-value ≤ 0.05. c Schematic summarizing the DEGs between the AF and NP at 23 M related to cell cycle regulation. d Volcano Plot,
showing up- and downregulated DEGs from the D + Q AF vs. Veh AF comparison, p ≤ 0.05. e Representative GO processes of upregulated genes from
D + Q AF vs. Veh AF. f Representative GO processes of downregulated genes from D + Q AF vs. Veh AF. g Volcano Plot, showing up- and downregulated
DEGs from the D + Q NP vs. Veh NP comparison, p-value ≤ 0.05. h Representative GO processes of downregulated genes from D + Q NP vs. Veh NP.
i Venn Diagram of common DEGs from D + Q AF vs. Veh AF and D + Q NP vs. Veh NP, p-value ≤ 0.05. j Representative GO processes of common DEGs
from panel I. k Representative DEGs from selected GO processes from panel j. p-values were calculated using eBayes ANOVA Method (unadjusted). GO
analysis was performed using the PANTHER Overrepresentation Test with GO Ontology database annotations and a binomial statistical test with
FDR ≤ 0.05. Source data are provided as a Source Data ﬁle.

Polg2, Hoxd10, Slc4a1, Xlr4b, Ppp1r10, Fbxw26, Tlr7, Snapc3,
Lrif1, Zkscan7, Tet2, Dmrta1, Zfp760, Ermap, Ogt, Ankzf1, Lipf,
Apol11b, Ddc, Il1rpl1, Adamts20, Eaf2, and Xlr4a.
To further explore the pathways commonly modulated in the
AF and NP by D + Q treatment, DEGs identiﬁed in both the AF
and NP D + Q vs. Veh. analyses were investigated. From this
analysis, 103 common DEGs emerged (Fig. 5i). Analysis of these
DEGs showed enrichment for cell death, response to cytokines,
regulation of RNA polymerase II, and ERK1/ERK2 cascade
pathways (Fig. 5j). The majority of DEGs related to cell death/
ERK cascade were downregulated in the D + Q groups and
included Cd14, Cebpb, Sfn, Gadd45g, Zfp36l, Ccnl1, Ctsh, and
Dusp6. Common DEGs related to the response to cytokines
included Junb, Psmb3, Nﬁl3, and Socs, whereas Ifrd1, Egr2, Vhl,
Klf6, Ets2, ler5, Fosl2, and Sesn2 were linked to regulation of
transcription (Fig. 5k). Overall, these results suggest that AF and
NP compartments in old mice possess distinct baseline
transcriptomic proﬁles, and D + Q treatment results in modulation of both unique and common pathways in each tissue.
Finally, to study the effect of D + Q treatment on agingassociated DEGs in the NP, we compared the DEGs modulated
by D + Q in 23 M mice with the transcriptomic signature of aging
in C576BL/6 mice (DEGs obtained from 23 M vs. 6 M naive BL6
NP: GSE134955, p < 0.05)28. The transcriptomic proﬁles of 23 M
and 6 M BL6 groups clustered distinctly, as demonstrated by
principal component and hierarchical clustering analyses (Fig. 6a,
b). Comparison of aging (23 M vs. 6 M) and D + Q modulated
DEGs showed 166 common genes (Fig. 6c). Interestingly, the
enrichment analysis of these common DEGs showed association
with negative regulation of apoptotic process, regulation of kinase
activity, regulation of cell differentiation, regulation of cell
population proliferation, cellular response to oxygen-containing
compound, and transcription by RNA polymerase II (Fig. 6c).
Noteworthy, the DEGs related to negative regulation of protein
kinase activity were Gadd45g, Dusp6, Dusp1, Taf7, Gprc5a,
Prkar1b, Gadd45a, and Deptor. Common DEGs related to
negative regulation of apoptotic process included Socs3, Jun,
Klf4, Mcl1 Ctsh, Axl, Myc, Atf5 and Adamts20. Whereas Atf3,
Nr4a1, Fos, Btg2, Maff, Egr1 and Egr2 were linked to skeletal
muscle cell differentiation (Fig. 6d). We then focused our analysis
on the group of common genes that were modulated in different
directions by aging and D + Q treatment (Fig. 6e). From this
analysis we found 27 genes upregulated during NP aging but
downregulated in the D + Q group, namely: Mbp, Axl, Cdh19,
Pdgfc, Deptor, Ctsh, Cpe, Jup, Ar, Ica1l, Cox5a, Snd1, Tubb2b,
Bbs4, and Psmd4 (Fig. 6e, f). Likewise, 19 genes including Dclk1,
Adamts20, E2f7, Fam19a1, Erc2, Adam4, Rnpc3, Cyp2c66, Tet2,
Rassf7, Dsg3, and Eddm3b were downregulated during aging but
were upregulated by D + Q (Fig. 6e, f). Overall, these results
suggest that D + Q modulates critical genes associated with aging
in the NP, suggesting its potential to slow intervertebral disc
degeneration during aging.

D + Q treatment mitigated an age-associated increase in circulatory levels of proinﬂammatory cytokines and Th17-related
proteins. To explore the impact of aging and D + Q treatment on
the status of systemic inﬂammation, we performed multiplex analysis
of several inﬂammatory molecules from plasma; Young (6 months)
vs. Old BL6 (23 months) and D + Q vs. Veh-14–23 M cohorts were
analyzed at the time of sacriﬁce. Data from 14–23 M treatment are
shown in Fig. 7, with data from the 6–23 M and 18–23 M shown in
Supplementary Fig. 5. Aged mice showed increases in: proinﬂammatory proteins IFN-γ, IL-2, IL-6, and TNF-α; cytokines IL27p28/IL-30, and MCP-1; and Th17 inﬂammatory mediators IL-16,
IL-17A, IL-17C, IL-21, and MIP-3α (Fig. 7a–c). An increase in antiinﬂammatory cytokine IL-10 was also noted with aging (Fig. 7a).
Interestingly, there was a signiﬁcant decrease in plasma levels of IL1β in all three D + Q-treated cohorts. Moreover, the 6–23 M D + Q
group showed diminished levels of IL-6 and TNF-α, and the
18–23 M D + Q cohort showed decreased levels of IL-2 relative to
the Veh group (Fig. 7a’ and Supplementary Fig. 5a–a’). Levels of IL15, IL-17A/F, IL-27p28/IL-30, IL-33, IP-10, MIP-2, MIP-1α/CCL3,
and MCP-1 did not show any signiﬁcant modulation between Veh
and D + Q groups for all 3 cohorts (Fig. 7b’ and Supplementary Fig.
5b–b’). Noteworthy, while the 18–23 M cohort did not present any
change in Th17-related molecules, the 14–23 M D + Q group
showed decreased levels in IL-16, IL-17E/IL-25, IL-21, IL-22, and IL31 (Fig. 7c’ and Supplementary Fig. 5c’). Similarly, the 6–23 M D + Q
group showed decreased levels of IL-17C, IL-22, and IL-31 (Supplementary Fig. 5b). These results suggest that despite increased
systemic inﬂammation with aging, D + Q treatment resulted in an
overall suppression of proinﬂammatory and Th17 mediators when
treatment was initiated at earlier time-points.
Prolonged D + Q treatment was well tolerated and beneﬁcial
effects varied between musculoskeletal tissue types. Previous
studies have shown a positive effect of D + Q treatment on different tissues. However, the optimal starting point and duration
of treatment in age-related-pathologies is not well
explored24,25,44. We therefore analyzed survival percentage,
change in body weight, vertebral bone properties, and osteoarthritis status in the knee joints in 23-month-old mice from three
treatment cohorts. Mice in D + Q-treated groups showed comparable survival rates to the Veh-treated animals and were in
accordance with strain life expectancy, as established by Jackson
Laboratory’s lifespan aging studies (Fig. 8a and Supplementary
Fig. 6a, d). D + Q-treated mice, with the exception of a trend in
female mice from the 6–23 M cohort, showed comparable weight
progression during aging when compared to Veh controls
(Fig. 8b, c and Supplementary Fig. 6b, c, e, f). As part of the frailty
index evaluation, the grip strength of the 6–23 M cohort was
measured. Interestingly, D + Q mice exerted greater force than
the Veh group (Supplementary Fig. 6g). We also assessed whether
D + Q treatment inﬂuenced disc height and disc height index
(DHI). While none of the 3 cohorts showed signiﬁcant differences
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Fig. 6 D + Q modulates aging-associated DEGs related to negative regulation of apoptotic process, regulation of kinase activity and regulation of cell
differentiation pathways. a, b PCA and hierarchical clustering of transcriptomic signature from 23 M vs. 6 M BL6 NP of deposited data in GSE134955,
p < 0.0528. c Venn diagram from intersection analysis of aging and D + Q modulated DEGs and the representative GO processes associated with the 166
common DEGs. d Representative common DEGs from selected GO processes from panel C. e Schematic of common DEGs showing directionality of
change in each experiment study (Aging vs. D + Q). f Representative DEGs with opposite modulation between aging and D + Q selected from panel e. pvalues were calculated using eBayes ANOVA Method (unadjusted). GO analysis was performed using the PANTHER Overrepresentation Test with GO
Ontology database annotations and a binomial statistical test with FDR ≤ 0.05. Source data are provided as a Source Data ﬁle.

in DHI, there was a trend towards increased disc height in
6–23 M D + Q-treated mice, compared to Veh-treated mice
(Fig. 8d and Supplementary Fig. 7a–c). Mice from the 18–23 M
D + Q cohort showed an increase in trabecular and cortical bone
thickness, as well as cortical bone area in males (Supplementary
Figs. 8 and 9). However, changes in trabecular and cortical bone
parameters were not observed between Veh- and D + Q-treated
mice in 6–23 M and 14–23 M cohorts (Fig. 8e–f and Supplementary Figs. 8 and 9). Similarly, bone mineral density (BMD)
analysis revealed no signiﬁcant changes between Veh and D + Q
groups across the three cohorts, and as expected, female but not
10

male mice showed an age-dependent (12 M vs. 23 M) decrease in
BMD (Supplementary Fig. 10). Additionally, the extent to which
D + Q mitigated the development of hindlimb OA was investigated. To provide a measure of cartilage degeneration, the
Osteoarthritis Research Society International (OARSI) score45
was summed across the four quadrants of the joint. The distribution of histological scores was similar between the Veh and
D + Q treatments in the 14–23 M cohort (Fig. 8g). The wide
distribution in scores was at least partly driven by sex-based
differences, but there was no trend towards improved scores in
either males or females with D + Q treatment in any of the
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Fig. 7 D + Q treatment prevented the age-associated systemic increase in proinﬂammatory molecules, cytokines, and Th17-related proteins. Multiplex
analysis of the main (a–a’) proinﬂammatory molecules, (b–b’) cytokines, and (c–c’) Th17-related proteins in plasma of young (6–12 M, n = 7), old (23 M,
n = 8), Veh-14–23 M (n = 8), and D + Q-14–23M (n = 7) groups. Two-tailed t-test or Mann–Whitney test were used as appropriate. Data are represented
as mean ± SEM. Source data are provided as a Source Data ﬁle.

treatment duration cohorts (Supplementary Fig. 11a, b). Noteworthy, unlike in the intervertebral disc, immunohistochemistry
analyses of senescence markers p16INK4a, p19ARF, and p21 in the
knee joints did not show any differences between 14 and 23 M
Veh- and DQ-treated mice (Supplementary Fig. 11c–e”). Taken
together, these results suggest that the prolonged D + Q treatment is well tolerated by mice. Interestingly, the treatment

showed differential effects on progression of aging pathologies
depending on the skeletal tissue type (i.e., disc, bone, or cartilage)
and starting point of treatment.
Discussion
Despite the staggering medical and societal costs of treating the
multitude of pathologies associated with intervertebral disc
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degeneration, there are few available clinical interventions, with
surgeries for symptomatic relief having suboptimal outcomes46.
Recent studies have suggested that senescence is an important
contributor to the progression of disc degeneration10,11,14. In this
study, we evaluated the therapeutic potential of the senolytic drug
combination Dasatinib and Quercetin, which has shown promising results in other tissues, to treat progression of age-

D+Q
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dependent disc degeneration. Additionally, we determined whether disc health outcomes vary depending on treatment starting
points, as well as the systemic impact of long-term D + Q
treatment. Our results show that the D + Q combination could
target senescence in the mouse disc, and these results provide
proof of principle that senolytics may be useful in mitigating agedependent disc degeneration by decreasing local senescence

NATURE COMMUNICATIONS | (2021)12:5213 | https://doi.org/10.1038/s41467-021-25453-2 | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25453-2

ARTICLE

Fig. 8 Long-term D + Q treatment was well tolerated by mice. a Survival curve from the 14–23 M Veh and. D + Q cohorts. b Weight progression in males
from 14–23 M Veh (n = 4) and D + Q (n = 4) cohorts. c Weight progression in females from 14–23 M Veh (n = 4) and D + Q (n = 3) cohorts. d Disc
height index comparison between 14 and 23 M Veh and D + Q groups. e Representative lumbar spine μCT pictures and bone properties:BV/TV, trabecular
thickness, and cortical bone thickness of Veh (n = 4) and D + Q (n = 4) males from the 14–23 M cohort, L4-L6/mouse. f Representative lumbar spine μCT
pictures and bone parameter analysis of BV/TV, trabecular thickness, and cortical bone thickness of Veh (n = 4) and D + Q (n = 3) females from the
14–23 M cohort, L4-L6/mouse. Scale bar e, f = 500 µm. t-test or Mann–Whitney test was used as appropriate. g Representative hindlimb histology from
the 14–23 M cohort as assessed by Safranin-O/Fast Green/Hematoxylin. Imaged from the lateral side of the joint. Anatomical and histological features of
the joint are denoted: Femur (F), Tibia (T), meniscus (M), tidemark (TM with diamond arrow), Saf-O loss (dotted arrow), and vertical clefts of cartilage
loss (solid arrow). OARSI grading (0–6) summed across 4 quadrants of joint from 14–23 M Veh (n = 7) and D + Q (n = 8) cohorts. Males denoted by
circles, females by triangles. Scale bar e, f = 500 µm, G = 20 µm. Two-tailed t-test or Mann–Whitney test was used as appropriate. Data are represented
as mean ± SEM. Source data are provided as a Source Data ﬁle.

Fig. 9 Senolytics ameliorate age-related disc degeneration. a Schematic summarizing the overall beneﬁcial effects of D + Q contributing to alleviation of
intervertebral disc degeneration during aging.

status, ﬁbrosis and matrix degradation, while promoting cell
viability, healthy matrix deposition and lower levels of systemic
inﬂammation (Fig. 9a).
Zhu et al.17 ﬁrst discussed D + Q treatment and introduced a
new class of drugs, senolytics, to selectively target senescent cells
by interfering with their pro-survival pathways. Among senolytics,
the D + Q combination has shown high efﬁciency in targeting
senescent cells23 and alleviating age-related pathologies24,25,47.
Noteworthy, previous studies have shown an increase in senescence during disc degeneration and aging in humans48 and
mice11. Additionally, systemic elimination of cells positive for
p16INK4a, an important marker of cell senescence in cartilaginous
tissues49, ameliorated disc degeneration in old mice10. Despite this
causative relationship between senescence and disc pathology,
long-term senolytic treatment has not been used to in pre-clinical
models of age-associated disc degeneration. We therefore treated
BL6 mice weekly with D + Q starting at 6 months (healthy adult
disc), 14 months (signs of early disc degeneration), and 18 months
of age (established disc degeneration)6 and analyzed all cohorts at
23 months of age, when advanced disc degeneration is evident.
Preservation of tissue and cell morphology and lower grades of
degeneration in 6–23 M and 14–23 M, but not 18–23 M, cohorts
clearly demonstrated that D + Q treatment slows the progression
of disc degeneration if treatment begins in the early stages of the
disease process but fails to rescue disc health after degeneration is
well-established. This is possibly due to a loss of cellular responsiveness and plasticity required to interfere with the degenerative
process. This observation has implications for future translational
studies, as a favorable outcome appears to be dependent on
identifying the optimal therapeutic window.

The ability of D + Q treatment to reduce the local senescence
burden in the disc compartments was tested. In accordance with
previous studies of other tissues, D + Q treatment successfully
targeted and reduced p16INK4a-, p19ARF-, and p21-positive cells
in the intervertebral disc. This may have preserved cellularity as
well as enabled a greater abundance of phenotypic markers in
D + Q-treated animals, substantiating studies of cartilage by Jeon
et al.20. Despite the decrease in senescence in the D + Q group,
we did not observe any changes in proliferation at 23-months.
This could be due to two reasons. First, the proliferation may
have occurred at an earlier time, and was therefore not evident at
23-months, and second, in mice the disc progenitor cells decline
with aging, leading to decreased proliferation and capacity to
renew resident cells50. Noteworthy, studies suggest that SASP is
the principal mechanism responsible for promoting local ﬁbrosis,
degeneration, and inﬂammation by senescent cells35,51. Levels of
IL-6 and MMP13, known products of the SASP, were lower in the
D + Q-treated group. However, IL-1β levels were higher in the
D + Q cohort when compared to the Vehicle but not the 1 y Ctr
group11,35. While this differed from the analysis of blood in these
mice, the effect in the disc was not unexpected, as a recent study
by Gorth et al.52 highlighted the importance of baseline IL-1
expression for the maintenance of disc health during aging52.
Likewise, a recent study on disc aging showed that IL-1 levels in
disc did not correlate with the abundance of senescence markers
p21 and p1611. Together, these ﬁndings suggest that unlike other
tissues IL-1 is not a characteristic SASP marker in the disc35.
Additionally, supporting previous studies of p16INK4a conditional
deletion in the adult disc and clearance of p16INK4a-positive cells
in human NP cell pellet cultures by RG-711210,11,16, D + Q
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mitigated levels of inﬂammatory mediators and metalloproteinases. Importantly, treatment preserved the number of disc cells
in part through a reduction in age-dependent cell death and
simultaneously maintained NP cell phenotypic marker expression. These results were similar to observations that intraarticular injection of a senolytic drug, UBX0101, preserved the
chondrocyte phenotype in a model of surgically induced
osteoarthritis20.
Since alterations in extracellular matrix composition and
integrity highly correlate with disc function7,28, healthy disc
matrix (COL 1, COL 2, and CS) and degenerative (COLX and
ARGxx) constituents were evaluated in treated mice37. While
D + Q treatment did not restore all matrix constituents to levels
seen in 1 y Ctr animals, there was a noticeable improvement over
the Veh group, with higher levels of COL 1 and CS and lower
levels of COLX and ARGxx. Patil et al.10 have shown reduced
levels of matrix catabolism in the disc when p16INK4a-positive
cells were systemically deleted. Noteworthy, we observed lower
incidence of NP ﬁbrosis in the D + Q-treated group. Interestingly, D + Q treatment in a bleomycin-induced idiopathic pulmonary ﬁbrosis mouse model was shown to successfully reduce
lung ﬁbrosis by decreasing local senescence burden, resulting in
improved health and function23. Importantly, our ﬁndings of
D + Q efﬁcacy in targeting SASP and restoring matrix homeostasis align with recent human trials that showed effectiveness of
this drug cocktail in targeting senescence and improving the
physical condition of patients suffering from idiopathic pulmonary ﬁbrosis and terminal renal disease26,27.
Although several studies have reported the potential of D + Q
treatment to prevent disease progression through the reduction of
senescence and degeneration, the molecular mechanisms modulated by these drugs at the transcriptomic level are unexplored.
Aging signiﬁcantly alters transcriptomic proﬁles of the intervertebral disc, with a consequent impact on morphological
phenotype28. While several studies have shown transcriptomic
differences between healthy AF and NP cells, during aging and
degeneration, the demarcation between these two compartments
is lost, and NP cells start to express markers reminiscent of
hypertrophic chondrocytes6,7,53. Our results clearly showed that
each compartment maintained expression of its unique markers
in old mice, but differences in cell cycle regulation were evident.
This result is of particular interest since D + Q is shown to target
a pro-survival network of tyrosine kinases, BCL-2, p53, p21,
serpine, PI3K/AKT, and consequently the cell cycle17,18. Thus, it
was not surprising that a high percentage of genes affected by
D + Q treatment were unique to the AF and NP compartments.
Importantly, the AF in D + Q mice showed similar increases in
DEGs related to response to stress, mitotic cell cycle, response to
DNA damage stimulus, and DNA repair as reported in other
tissues17. Likewise, previous studies with ERCC-/ Δ mice showed
higher grades of disc degeneration, senescent cells, and matrix
catabolism9,54. Additionally, downregulated DEGs showed
enrichment for several pathways related to cell respiration, suggesting that inhibition of oxidative metabolism is crucial to
maintain disc homeostasis55–57. In the NP compartment, in
agreement with lower histological grades of degeneration and
COL X abundance, a marker of hypertrophic chondrocytes7,
downregulated DEGs showed enrichment in skeletal cell differentiation. Noteworthy, NP and AF tissues showed modulation of
cell death, response to cytokines along with regulation of RNA
polymerase, and the ERK1/ERK2 cascade. These transcriptomic
studies are particularly interesting as they underscore common
mechanisms regulated by D + Q, independent of the tissue type,
and further support TUNEL staining and SASP ﬁndings17,20,24.
Moreover, by comparing DEGs modulated by D + Q treatment to
aging-dependent transcriptomic signature, we discovered that
14

D + Q promoted negative regulation of protein kinase activity
(Dasatinib targets senescence by inhibiting tyrosine kinase
protein17) and promoted cell viability by negatively regulating
apoptotic process and modulated NP cell differentiation pathways. Together, these results provide clear evidence that, in
addition to tissue-speciﬁc effects, D + Q treatment modulates
common biological pathways, partially explaining the overall
protective effect observed in different organ systems.
Since most studies have studied shorter term D + Q administration, we sought to evaluate the systemic impact of long-term
treatment on other organ systems. Previously, D + Q treatment
improved vasomotor function by increasing nitric oxide bioavailability and reducing aortic calciﬁcation during aging58. Analysis of circulatory inﬂammatory mediators clearly showed a
signiﬁcant decrease in critical proinﬂammatory proteins and
Th17 mediators in all treatment cohorts. Noteworthy, the 6–23 M
cohort presented more pronounced downregulation of these
factors, suggesting that longer durations of D + Q treatment
contributed to better control of systemic inﬂammation. SASP can
promote systemic inﬂammation and immune system activity35.
Indeed, some studies have explored the effects of senolytic and
senostatic drugs that target SASP secretion to decrease tissue
inﬂammation and enhance the immune system activity44,51,59.
Noteworthy, the intervertebral disc is an avascular and constrained tissue that exhibits insensitivity to systemic
inﬂammation60,61. This fact may explain the differences seen
between systemic- and disc-level modulation of IL-6 and IL-1.
Despite these differences, it was interesting to observe that D + Q
treatment promoted downregulation of proinﬂammatory signaling in the disc and in circulation. While it is important to
acknowledge that the possible systemic effects of D + Q treatment
may contribute to ameliorating disc degeneration during aging,
senolysis plays a key role in this process since 18–23 M cohort,
which did not evidence decreased senescence burden also lacked
rescue of aged-associated degeneration. Moreover, along with the
beneﬁcial systemic effects of D + Q treatment, we observed an
increase in physical strength of mice in the 6–23 M cohort. This
was important, since strength is one of the most accurate indicators of systemic aging62,63, and similar results of improved
physical performance and decreased SASP expression in mice
treated with D + Q from 20 to 24 months have been noted25.
Furthermore, recent human trials of idiopathic pulmonary
ﬁbrosis using D + Q treatment have shown improvements in
patients’ physical condition26,27. Importantly, long term treatment of mice in our study did not show noxious effects, underscoring the safety of D + Q treatment. Additionally, and in
agreement with a previous report, our 18–23 M cohort showed
improved vertebral bone quality parameters24. Surprisingly, we
did not observe the same beneﬁcial effects on vertebral bone
quality in 6–23 M and 14–23 M cohorts. Interestingly, a recent
study suggested that targeting senescent osteoclasts did not promote increased bone quality in old mice64. It is plausible an
optimal treatment window is necessary to target-speciﬁc senescent populations within bone, affecting bone homeostasis during
aging. A tissue that is similar to the intervertebral disc, due to its
anatomy and matrix composition, is the articular cartilage. Jeon
et al.20 have previously shown promising results of intra-articular
injections of senolytic compound UBX0101 ameliorating
osteoarthritis progression in an ACL injury mouse model. In our
study, while OA development was seen with aging (especially in
male mice), it was surprising that no signiﬁcant improvements in
age-related osteoarthritis were noted in our D + Q treatment
cohorts. Since there were no changes in senescence status in
cartilage, it is plausible that similar to AF and NP cells, chondrocytes exhibit differential sensitivity and response to D + Q
treatment, making drug choice and administration method
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important factors while devising senolytic treatments for speciﬁc
tissues. Indeed, more than 60% of the senescent chondrocytes
from within murine cartilage explants were cleared with 3 days of
navitoclax treatment65, but this senolytic was not directly compared to D + Q in that study. Another possibility is that intraarticular injection of D + Q would be needed to obtain sufﬁcient
drug concentration in the joint. Importantly, some studies have
suggested that different senolytic compounds might present
diverse efﬁcacy depending on the target tissue23,66. Additionally,
based on our results the beneﬁcial effects of systemic administration of D + Q were clearly dependent on the analyzed tissue
type and duration of the treatment.
In summary, systemic administration of D + Q22,67 posits an
exciting therapeutic approach to treating disc degeneration,
without the inherent risks associated with invasive surgical
interventions. The potential beneﬁts of D + Q treatment include
alleviation of disc degeneration, reduction in systemic inﬂammation, and improved physical condition during aging. We also
provide insights into tissue-speciﬁc effects of D + Q treatment
and underscore the importance of treatment duration. These
issues will be critical to consider during future pre-clinical studies
in large animal models of disc degeneration.
Methods
Mice, treatment, and study design. All animal experiments were performed
under Institutional Animal Care and Use Committee (IACUC) protocols approved
by the Thomas Jefferson University, and all the guidelines for animal experiments
were adhered to. 6-month-old (healthy adult, 15 females, 13 males), 14-month-old
(middle-aged, 7 females, 8 males), and 18-month-old (aged, 7 females, 13 males)
C57BL/6 mice were obtained from the aged rodent colony at the National Institutes
of Aging (NIA), aged to 23 months (old age), and analyzed. These time-points were
chosen based on previous studies showing progressive changes in morphological
features of mouse lumbar discs at these time-points6. The endpoint of 23 months
was selected according to guidelines on life phases and maturational rates for the
C57BL/6J strain compared to humans68. 1-year-old C57BL/6 mice were used as a
baseline reference for middle-aged, healthy adult discs to address age-related
directionality of changes69. Animals were randomly divided into 2 groups per
timepoint and received weekly intraperitoneal injections of either Vehicle (1:2 PBS
and 1:2 DMSO) or 5 mg/kg Dasatinib (Sigma-Aldrich, CDS023389) plus 50 mg/kg
Quercetin (Sigma-Aldrich, Q4951) until they were 23 months old. Senolytic drug
concentrations were based on previous studies demonstrating a stronger senolytic
effect of D + Q in combination at these concentrations in alleviating the senescence
burden in different tissues17,23. To ascertain how baseline degeneration status of
discs affects the success of the D + Q therapy in ameliorating an age-dependent
progression of degeneration, mice were treated before presenting signs of degeneration (6 months), as they evidence early degenerative changes (14 months), and
when established age-related degeneration is observed in the disc (18 months)6.
Mouse weights were recorded weekly, and the number of animals in each cohort
was as follows: 6–23 M Veh (n = 13), D + Q (n = 15); 14–23 M Veh (n = 8),
D + Q (n = 7); 18–23 M Veh (n = 11), D + Q (n = 9).
Grip test analysis. Grip strength was measured using DFIS-2 Series Digital Force
Gauge (Columbus Instruments, OH), as reported previously70. Brieﬂy, a digital
force gauge is attached to a triangular metal pull bar that allows for the transduction of force from the mouse to the gauge. This apparatus measures the
strength with which the mouse can grasp and hold on to a thin metal bar. Mice
from the 6–23 M cohort were acclimated for a week and tested just before
euthanasia. In each trial, the mouse was allowed to grab the bar with one forepaw
and was then quickly pulled away from the gauge, so its grip was released, providing a measurement of the force with which the mouse gripped the bar. A
blinded examiner performed three trials for each forepaw, with an inter-trial
interval of at least 60 s.
Histological analysis. Dissected spines were ﬁxed in 4% PFA in PBS for 48 hours,
decalciﬁed in 20% EDTA, and embedded in parafﬁn. Seven micrometer midcoronal sections were cut from three lumbar levels (L3-6) of each mouse, stained
with Safranin-O/Fast Green/Hematoxylin for histological assessment and with
Picrosirius Red for collagen ﬁber characterization. Safranin-O staining was visualized using an Axio Imager 2 microscope (Carl Zeiss) using 5×/0.15 N-Achroplan
or 20×/0.5 EC Plan-Neoﬂuar objectives (Carl Zeiss) and Zen2TM software (Carl
Zeiss AG, Germany). Mid-coronal sections from ≥3 lumbar discs (L3-S1) per
mouse were scored using a modiﬁed Thompson grading scale by four blinded
observers7. The heterogeneity of collagen organization was evaluated using a
polarizing, light microscope, Eclipse LV100 POL (Nikon, Tokyo, Japan) with a 10x/
0.25 Pol/WD 7.0 objective and DS-Fi2 camera and images analyzed in the NIS
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Elements AR 4.50.00 software (Nikon, Tokyo, Japan). Under polarized light,
stained collagen bundles appear either green, yellow, or red and correlate to the
ﬁber thickness. Color threshold levels were maintained constant between all analyzed images.
Imaging FTIR spectroscopy and spectral clustering. Five micrometer deparafﬁnized
sections of decalciﬁed lumbar disc tissues were collected from vehicle and D + Q
14–23 M cohort group (n = 3 disc/animal, 6 animals/group) and used to acquire
FTIR spectral imaging data using methods previously described40. Data was collected using Spectrum Spotlight 400 FTIR Imaging system (Perkin Elmer, Shelton,
CT), operating in the mid-IR region of 4,000 - 850 cm−1 at a spectral resolution of
8 cm−1 and spatial resolution of 25 μm. Spectra were collected across the mid-IR
region of three consecutive sections/disc to minimize section-based variation.
Using the ISys Chemical Imaging Analysis software (v. 5.0.0.14) mean secondderivative absorbances in the collagen side-chain vibration (1338 cm−1) regions
were quantiﬁed and compared in Veh and D + Q AF and NP compartments. The
preprocessed spectra were used for K-means cluster analysis to deﬁne anatomical
regions and tissue types within the tissue section spectral images7, which represent
collagen peak. Clustering images were obtain using Spectrum Image Software.
Immunohistology and cell number measurements. Deparafﬁnized sections following
antigen retrieval were blocked in 5% normal serum in PBS-T, and incubated with
antibodies against collagen I (1:100, Abcam ab34710), collagen II (1:400, Fitzgerald
70R-CR008), COMP (1:200, Abcam ab231977), collagen X (1:500, Abcam
ab58632), chondroitin sulfate (1:300, Abcam ab11570); CA3 (1:150, Santa Cruz),
p16 (1:50, Abcam ab211542), p19 (1:100, Novus NB200-106), p21 (1:200, Novus
NB100-1941), p-H2AX (1:50, Cell Signaling 9718), RB (1:50, Abcam ab181616),
pRB (1:50, Cell Signaling D20B12), Ki67 (1:100, Abcam ab15580), IL-1β (1:100,
Novus NB600-633), IL-6 (1:50, Novus NB600-1131), and MMP13 (1:150, Abcam
ab39012). For GLUT-1 (1:200, Abcam, ab40084) and ARGxx (1:200, Abcam,
ab3773) staining, a MOM kit (Vector laboratories, BMK-2202) was used for
blocking and primary antibody incubation. Tissue sections were washed and
incubated with species-appropriate Alexa Fluor-594 conjugated secondary antibodies (Jackson ImmunoResearch Lab, Inc.,1:700). F-CHP (3Helix) staining was
performed according to the manufacturer’s protocol. The sections were mounted
with ProLong® Gold Antifade Mountant with DAPI (Fisher Scientiﬁc, P36934),
visualized with Axio Imager 2 microscope using 5×/0.15 N-Achroplan or 20×/0.5
EC Plan-Neoﬂuar objectives, and images were captured with Axiocam MRm
monochromatic camera (Carl Zeiss) and Zen2TM software (Carl Zeiss AG, Germany). Both caudal (Ca5-8) and lumbar (L3-S1) discs were used for the analysis.
Staining area and cell number quantiﬁcation were performed using the ImageJ
software, v1.53e, last access 12/05/2021 (http://rsb.info.nih.gov/ij/). The boundaries
of the NP and AF were digitally traced using the Freehand Tool. Images with
selected ROI (NP, AF, and EP) were thresholded to subtract the background,
transformed into binary format, and then staining area and cell number were
calculated using the analyze particle function in Image J software, v1.53e, last access
12/05/2021 (http://rsb.info.nih.gov/ij/)56.
TUNEL assay. TUNEL staining was performed using the In situ cell death detection
kit (Roche Diagnostic). Brieﬂy, sections were deparafﬁnized and permeabilized
using Proteinase K (20 μg/mL) for 15 min, and the TUNEL assay was carried out
per the manufacturer’s protocol. Sections were washed and mounted with ProLong® Gold Antifade Mountant with DAPI and visualized and imaged with the
Axio Imager 2 microscope.
Tissue RNA isolation and real-time RT-PCR analysis. NP and AF tissues were
dissected from lumbar (L1-3) and caudal discs (Ca1-5) of 23-month-old Veh and
D + Q animals from the 14–23 M cohort (Veh = 5 and D + Q = 4). Pooled tissue
from a single animal served as an individual sample. Samples were homogenized,
and total RNA was extracted using the RNeasy® Mini kit (Qiagen). The puriﬁed,
DNA-free RNA was converted to cDNA using the EcoDry™ Premix (Clontech).
Template cDNA and gene-speciﬁc primers (IDT, IN) were added to Power SYBR
Green master mix, and expression was quantiﬁed using the Step One Plus Realtime PCR System (Applied Biosystems).
Microarray analysis and enriched pathways. Total RNA with RIN > 4 was used for
the analysis. Fragmented biotin-labeled cDNA was synthesized using the GeneChip
WT Plus kit according to the ABI protocol (Thermo Fisher). Gene chips (Mouse
Clariom S) were hybridized with biotin-labeled cDNA. Arrays were washed and
stained with GeneChip hybridization wash & stain kit and scanned on an Affymetrix Gene Chip Scanner 3000 7G, using the Command Console Software.
Quality Control of the experiment was performed in the Expression Console
Software v 1.4.1.CHP ﬁles were generated by sst-rma normalization from Affymetrix. CEL ﬁles, using the Expression Console Software. Only protein-coding
genes were included in the analyses. Detection above background higher than 50%
was used for Signiﬁcance Analysis of Microarrays (SAM), and the p-value was set
at 5%. Biological process enrichment analysis was performed using the PANTHER
Overrepresentation Test with GO Ontology database annotations and a binomial
statistical test with FDR ≤ 0.05. Analyses and visualizations were conducted in the
Affymetrix Transcriptome Analysis Console (TAC) 4.0 software. Pathway
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schematic analyses were obtained using the TAC. The array data generated during
this study is available in a public repository, GEO database, GSE154619.
To study how D + Q treatment modulated aging related transcriptome changes
in NP tissue, we analyzed the array results previously deposited in GEO database:
GSE134955, p < 0.05 (23 M C57BL/6 mice n = 7 vs. 6M C57BL/6 mice n = 7)28 and
compared them to D + Q modulated DEGs form this study, GSE154619.
Micro-CT analysis. Micro-CT (μCT) scanning (Bruker SkyScan 1275, version
1.0.16.0) was performed on ﬁxed spines using parameters of 50 kV (voltage) and
200 μA (current) at 15 μm resolution. Images were reconstructed using the nRecon
program (Version: 1.7.1.0, Bruker) and analysis was performed using CTan (version 1.17.7.2 + 64 bit Bruker micro-CT). Transverse cross-sectional images were
analyzed to evaluate trabecular and cortical bone morphology. For trabecular
analysis, a region of interest (ROI) was selected by contouring the boundary
between trabecular and cortical bone throughout the vertebral body. The 3D
datasets were assessed for bone volume fraction (BV/ TV), trabecular thickness
(Tb. Th), trabecular number (Tb. N), and trabecular separation (Tb. Sp). For
cortical bone analyses, 2D assessments were computed for cortical bone volume
(BV), cross-sectional thickness (Cs.Th), polar moment of inertia (MMI), and
Eccentricity (Ecc). Disc height and vertebral length were measured at three
different points equidistant from the center of the bone on the sagittal plane.
Disc height index (DHI) was calculated using equation: Disc Height Index
(DHI) = 2 × (DH1 + DH2 + DH3)/(A1 + A2 + A3 + B1 + B2 + B3) where A and
B represent the length of the vertebral bone immediately rostral and caudal to the
intervertebral disc, respectively; and DH represents the disc height between adjacent vertebrae7,71.
Circulating cytokine analysis. Blood was collected by heart puncture following
sacriﬁce and centrifuged at 1500 × g, at 4 °C for 15 min to isolate the plasma, which
was stored at −80 °C until analysis. Levels of proinﬂammatory proteins, cytokines,
and Th17 mediators were analyzed using V‐PLEX Mouse Cytokine 29‐Plex Kit
(Meso Scale Diagnostics, Rockville, MD) and Discovery Workbench 4.0 software
according to manufacturer’s speciﬁcations.
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Statistics and reproducibility. All statistical analyses were performed using Prism7
(GraphPad, La Jolla). Data are represented as mean ± SEM. Data distribution was
assessed with the Shapiro–-Wilk normality test, and the differences between the
two groups were analyzed by t-test or Mann–Whitney, as appropriate. The differences between three groups were analyzed by ANOVA or Kruskal–Wallis for
non-normally distributed data, followed by a Dunn’s multiple comparison test. A
χ2-test was used to analyze the differences between the distribution of percentages.
p ≤ 0.05 was considered a statistically signiﬁcant difference. Reported results were
consistently replicated across multiple experiments with all replicates generating
similar results: 6–23 M cohorts: 4 independent experiments, with 3–4 animals per
group (Veh and D + Q); 14–23 M cohorts: 2 independent experiments, with 3–4
animals per group (Veh and D + Q); 18–23 M cohorts: 4 independent experiments,
with 2–3 animals per group (Veh and D + Q).
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
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Data availability
The microarray dataset data generated in this study is deposited in the GEO database
under accession code GSE154619. There are no access restrictions to any of the processed
and raw data. Source data are provided with this paper.
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